Your browser doesn't support javascript.
A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination.
Brito, Sérgio; Ferreira, Nuno; Mateus, Sofia; Bernardo, Manuela; Pinto, Beatriz; Lourenço, Ana; Grenho, Fátima.
  • Brito S; Internal Medicine, Hospital CUF Tejo, Lisbon, PRT.
  • Ferreira N; Internal Medicine, Hospital CUF Tejo, Lisbon, PRT.
  • Mateus S; Internal Medicine, Hospital CUF Tejo, Lisbon, PRT.
  • Bernardo M; Hematology and Oncology, Hospital CUF Tejo, Lisbon, PRT.
  • Pinto B; Pharmacy, Hospital CUF Tejo, Lisbon, PRT.
  • Lourenço A; Internal Medicine, Hospital CUF Tejo, Lisbon, PRT.
  • Grenho F; Internal Medicine, Hospital CUF Tejo, Lisbon, PRT.
Cureus ; 13(5): e15035, 2021 May 15.
Article in English | MEDLINE | ID: covidwho-1278702
ABSTRACT
Autoimmune hemolytic anemia (AIHA) is a condition characterized by the increased destruction of red blood cells (RBCs) mediated by anti-erythrocyte autoantibodies with or without complement activation. Its clinical presentation is heterogeneous, ranging from asymptomatic to severe forms with fatal outcomes, and it can be either idiopathic or secondary to a coexisting disorder. In this report, we present a case of a patient who suffered from acute and severe AIHA after receiving the second dose of the coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccine.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Topics: Vaccines Language: English Journal: Cureus Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Topics: Vaccines Language: English Journal: Cureus Year: 2021 Document Type: Article